AR072842A1 - Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico - Google Patents

Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico

Info

Publication number
AR072842A1
AR072842A1 ARP090102847A AR072842A1 AR 072842 A1 AR072842 A1 AR 072842A1 AR P090102847 A ARP090102847 A AR P090102847A AR 072842 A1 AR072842 A1 AR 072842A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically active
pharmaceutical composition
active ingredient
peptidic
ingredient
Prior art date
Application number
Other languages
English (en)
Inventor
Muneo Nonomura
Yasuhiro Hiraishi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR072842A1 publication Critical patent/AR072842A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Una composicion farmacéutica o una preparacion solida que contiene un ingrediente farmacéuticamente activo estabilizado y un método para estabilizar la misma. Una composicion farmacéutica estabilizada que comprende un ingrediente farmacéuticamente activo no peptídico que tiene un grupo amino primario o secundario, un excipiente y un compuesto acídico. Además, una preparacion solida que contiene un ingrediente farmacéuticamente activo, oxido de titanio, un plastificante y un ácido orgánico de cadena puede aumentar la estabilidad del ingrediente farmacéuticamente activo durante una irradiacion luminosa.
ARP090102847 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico AR072842A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28

Publications (1)

Publication Number Publication Date
AR072842A1 true AR072842A1 (es) 2010-09-22

Family

ID=41327301

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102847 AR072842A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico

Country Status (29)

Country Link
US (2) US9186411B2 (es)
EP (2) EP2564833B1 (es)
JP (2) JP5295356B2 (es)
KR (1) KR20110042334A (es)
CN (3) CN104784180A (es)
AR (1) AR072842A1 (es)
AU (1) AU2009277443A1 (es)
BR (1) BRPI0916689A2 (es)
CA (2) CA2936400C (es)
CL (1) CL2011000170A1 (es)
CO (1) CO6290638A2 (es)
CR (1) CR20110110A (es)
DO (2) DOP2011000033A (es)
EA (2) EA201201451A1 (es)
EC (1) ECSP11010855A (es)
ES (2) ES2669592T3 (es)
GE (2) GEP20146122B (es)
IL (2) IL210735A0 (es)
MA (1) MA32556B1 (es)
MX (1) MX2011000757A (es)
MY (2) MY169461A (es)
NZ (2) NZ591344A (es)
PE (3) PE20110591A1 (es)
SG (1) SG186685A1 (es)
TW (2) TW201010992A (es)
UA (1) UA103332C2 (es)
UY (1) UY32008A (es)
WO (1) WO2010013823A2 (es)
ZA (1) ZA201101198B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254322B (zh) * 2012-02-15 2017-06-13 武田药品工业株式会社 片剂
SG11201408511QA (en) 2012-06-27 2015-01-29 Takeda Pharmaceutical Liquid preparations of amines and organic acids stabilized by salts
RU2589701C1 (ru) 2012-09-19 2016-07-10 Тайхо Фармасьютикал Ко., Лтд. Фармацевтическая композиция для перорального введения с улучшенными растворимостью и/или всасываемостью
US20150080845A1 (en) * 2013-03-14 2015-03-19 Allergan, Inc. Polymer system for securing implants in syringe needles
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
CN108135915B (zh) 2015-07-30 2021-06-25 武田药品工业株式会社 片剂
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
JP7013454B2 (ja) * 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
AU2018275631A1 (en) 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
WO2019013310A1 (en) * 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60125026T2 (de) 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
CN1638773A (zh) 2001-07-30 2005-07-13 三菱制药株式会社 以氨基苯磺酸衍生物作为活性成分的药物制剂
CN1571664A (zh) 2001-10-17 2005-01-26 久光制药株式会社 经皮吸收型制剂
AU2003217820A1 (en) 2002-02-28 2003-09-16 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
EP1485094B2 (de) 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
AR045062A1 (es) 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
JP5168712B2 (ja) 2004-04-01 2013-03-27 味の素株式会社 ナテグリニド含有製剤
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
WO2006036024A1 (ja) 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited プロトンポンプ阻害薬
CA2582300A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
WO2007023931A1 (ja) 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. 血中アルコール濃度上昇抑制用組成物
PL1919865T3 (pl) * 2005-08-30 2011-09-30 Takeda Pharmaceuticals Co 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania
US20090104264A1 (en) 2005-12-28 2009-04-23 Takeda Pharmaceutical Company Limited Controlled release solid preparation
CA2662938A1 (en) 2006-09-15 2008-03-20 Astellas Pharma Inc. Light-stable solid pharmaceutical composition of ramosetron
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
EP3162798B1 (en) 2007-09-28 2021-04-14 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compound
JP5345140B2 (ja) 2007-09-28 2013-11-20 武田薬品工業株式会社 プロトンポンプ阻害剤としての５員複素環化合物
US20110059176A1 (en) 2007-11-22 2011-03-10 The University Of Tokyo Material for preventing tissue adhesion and material for preventing joint contracture

Also Published As

Publication number Publication date
MY156305A (en) 2016-01-29
IL228817A0 (en) 2013-12-31
GEP20146166B (en) 2014-09-25
WO2010013823A3 (en) 2010-04-15
EP2309985A2 (en) 2011-04-20
DOP2011000033A (es) 2011-04-15
US20110124687A1 (en) 2011-05-26
JP2013047239A (ja) 2013-03-07
CR20110110A (es) 2011-04-28
UY32008A (es) 2010-02-26
MY169461A (en) 2019-04-11
ECSP11010855A (es) 2011-03-31
MA32556B1 (fr) 2011-08-01
CN102743330B (zh) 2016-03-23
EP2564833B1 (en) 2017-12-20
MX2011000757A (es) 2011-02-24
AU2009277443A1 (en) 2010-02-04
ES2669592T3 (es) 2018-05-28
CL2011000170A1 (es) 2011-06-10
TW201431552A (zh) 2014-08-16
KR20110042334A (ko) 2011-04-26
JP5295356B2 (ja) 2013-09-18
SG186685A1 (en) 2013-01-30
JP5593363B2 (ja) 2014-09-24
WO2010013823A2 (en) 2010-02-04
ZA201101198B (en) 2012-05-30
UA103332C2 (ru) 2013-10-10
CA2936400A1 (en) 2010-02-04
CA2936400C (en) 2018-03-27
DOP2013000172A (es) 2013-11-15
CA2732243A1 (en) 2010-02-04
ES2660962T3 (es) 2018-03-26
CN104784180A (zh) 2015-07-22
GEP20146122B (en) 2014-07-25
CO6290638A2 (es) 2011-06-20
EP2309985B1 (en) 2018-03-14
PE20140977A1 (es) 2014-08-20
JP2011529445A (ja) 2011-12-08
US20130261156A1 (en) 2013-10-03
EA201201451A1 (ru) 2013-07-30
PE20141585A1 (es) 2014-11-13
EP2564833A1 (en) 2013-03-06
PE20110591A1 (es) 2011-09-15
BRPI0916689A2 (pt) 2015-11-17
NZ602592A (en) 2014-01-31
CN102164581A (zh) 2011-08-24
NZ591344A (en) 2013-03-28
US9186411B2 (en) 2015-11-17
CN102743330A (zh) 2012-10-24
IL210735A0 (en) 2011-03-31
CA2732243C (en) 2016-11-29
TW201010992A (en) 2010-03-16
EA201170272A1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
AR072842A1 (es) Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
EA201492214A1 (ru) Ингибиторы вируса гепатита с
CR11137A (es) Valvulas prosteticas de corazon
ECSP109984A (es) Composición farmacéutica mejorada que contiene dihidropiridina, antagonista del canal de calcio y el método para su preparación
UY32062A (es) Inhibidores de beta-secretasa
CL2011000314A1 (es) Composición farmacéutica estable que comprende linaclotida; método de preparación; y uso para preparar un medicamento útil para tratar un desorden gastrointestinal.
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
UY32424A (es) Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
AR076305A1 (es) Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
AR082875A1 (es) (s)-(4-fluorofenil)(4-((5-metil-1h-pirazol-3-il)amino)quinazolin-2-il)metanol opticamente activo, composiciones farmaceuticas que lo contienen, metodo para prepararlo y uso del mismo como agentes anticancer o antiinflamatorio
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
TR201803451T4 (tr) Olmesartan formülasyonlari.
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης
MX2016008729A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.

Legal Events

Date Code Title Description
FB Suspension of granting procedure